The Experts below are selected from a list of 82884 Experts worldwide ranked by ideXlab platform

Chung Feng Huang - One of the best experts on this subject based on the ideXlab platform.

  • Interleukin 28B genetic variants in identification of hepatitis c virus genotype 1 patients responding to 24 weeks peginterferon ribavirin
    Journal of Hepatology, 2012
    Co-Authors: Chung Feng Huang, Jee-fu Huang, Jeng Fu Yang, Ming Yen Hsieh, Zu Yau Lin, Shinn Cherng Chen, L.-y. Wang, Suh Hang Hank Juo, Ku Chung Chen, Wan-long Chuang
    Abstract:

    Background & Aims A substantial proportion of hepatitis C virus genotype 1 (HCV-1) patients achieved a sustained virological response (SVR, HCV RNA seronegative throughout 24weeks of post-treatment follow-up) after 24weeks peginterferon/ribavirin therapy. We explored the role of Interleukin-28B genotype in identifying patients who responded to the regimen. Methods Interleukin-28B rs8099917 genotype was determined in 226 HCV-1 patients with 24weeks peginterferon/ribavirin. Results Compared to patients with rs8099917 TG/GG genotype, those with TT genotype had significantly higher rapid virological response (RVR, HCV RNA seronegative at treatment week 4, 54.0% vs. 17.9%, p vs . 25.6%, p vs . 54.5%, p =0.01). Logistic regression analysis revealed that the strongest factor predictive of a RVR was the carriage of rs8099917 TT genotype (odds ratio/ 95% confidence intervals [OR/CI]: 6.24/2.34–16.63), followed by lower viral loads (OR/CI: 5.29/2.81–9.93) and age (OR/CI:0.94/0.91–9.97). The most important factor predictive of an SVR was the attainment of a RVR (OR/CI: 22.23/9.22–53.58), followed by the carriage of rs8099917 TT genotype (OR/CI: 3.38/1.18–9.65), lower viral loads (OR/CI: 2.23/1.00–4.93) and ribavirin exposure dose (OR/CI: 1.17/1.06–1.30). The determinant power of rs8099917 genotype on SVR was mainly restricted to non-RVR patients, particularly those with higher baseline viral loads. Combination of the two pretreatment predictors, Interleukin-28B genotype and baseline viral loads, could predict treatment efficacy with a positive predictive value of 80% and a negative predictive value of 91%. Conclusions Interleukin-28B genotype could help identifying patients who are or are not candidates for an abbreviated regimen before treatment.

  • Host Interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1.
    Antiviral research, 2011
    Co-Authors: Chung Feng Huang, Jee-fu Huang, Jeng Fu Yang, Ming Yen Hsieh, Zu Yau Lin, Shinn Cherng Chen, L.-y. Wang, Ming-lun Yeh, Edward Hsi, Suh Hang Hank Juo
    Abstract:

    Abstract Background Both Interleukin-28B genetic variants and on-treatment virological responses are factors predictive of treatment outcome in hepatitis C virus genotype 1 (HCV-1) patients. We aimed to compare the clinical significance of the two factors. Methods Rs8099917 genotype and on-treatment responses were determined in 182 HCV-1 patients with 48-week peginterferon/ribavirin. Results Comparing to patients with rs8099917 TG/GG genotype, those with TT genotype had significantly higher rapid virological response (RVR, 46.2% vs. 19.2%, P  = 0.01) and sustained virological response (SVR, 85.3% vs. 42.3%, P Conclusions Rs8099917 TT genotype is significantly independently predictive of on-treatment virological responses, which were the major determinants of an SVR, in Asian HCV-1 patients.

  • Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.
    Journal of hepatology, 2011
    Co-Authors: Chung Feng Huang, Jee-fu Huang, Jeng Fu Yang, Ming Yen Hsieh, Zu Yau Lin, Shinn Cherng Chen, L.-y. Wang, Suh Hang Hank Juo, Ku Chung Chen, Wan-long Chuang
    Abstract:

    Background & Aims A substantial proportion of hepatitis C virus genotype 1 (HCV-1) patients achieved a sustained virological response (SVR, HCV RNA seronegative throughout 24weeks of post-treatment follow-up) after 24weeks peginterferon/ribavirin therapy. We explored the role of Interleukin-28B genotype in identifying patients who responded to the regimen. Methods Interleukin-28B rs8099917 genotype was determined in 226 HCV-1 patients with 24weeks peginterferon/ribavirin. Results Compared to patients with rs8099917 TG/GG genotype, those with TT genotype had significantly higher rapid virological response (RVR, HCV RNA seronegative at treatment week 4, 54.0% vs. 17.9%, p vs . 25.6%, p vs . 54.5%, p =0.01). Logistic regression analysis revealed that the strongest factor predictive of a RVR was the carriage of rs8099917 TT genotype (odds ratio/ 95% confidence intervals [OR/CI]: 6.24/2.34–16.63), followed by lower viral loads (OR/CI: 5.29/2.81–9.93) and age (OR/CI:0.94/0.91–9.97). The most important factor predictive of an SVR was the attainment of a RVR (OR/CI: 22.23/9.22–53.58), followed by the carriage of rs8099917 TT genotype (OR/CI: 3.38/1.18–9.65), lower viral loads (OR/CI: 2.23/1.00–4.93) and ribavirin exposure dose (OR/CI: 1.17/1.06–1.30). The determinant power of rs8099917 genotype on SVR was mainly restricted to non-RVR patients, particularly those with higher baseline viral loads. Combination of the two pretreatment predictors, Interleukin-28B genotype and baseline viral loads, could predict treatment efficacy with a positive predictive value of 80% and a negative predictive value of 91%. Conclusions Interleukin-28B genotype could help identifying patients who are or are not candidates for an abbreviated regimen before treatment.

  • Role of Interleukin‐28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients
    Hepatology (Baltimore Md.), 2011
    Co-Authors: Chung Feng Huang, Jee-fu Huang, Jeng Fu Yang, Zu Yau Lin, Shinn Cherng Chen, L.-y. Wang, Ning-chia Chang, Ming-yuh Hsieh, Wen-yu Chang
    Abstract:

    Genome-wide association studies have linked single nucleotide polymorphisms (SNPs) near the Interleukin-28B gene to the hepatitis C virus genotype 1 (HCV-1) response to peginterferon/ribavirin treatment. We aimed to explore the impact on the treatment outcomes of Asian HCV-2 patients. We determined rs8105790, rs8099917, rs4803219, and rs10853728 to be candidate SNPs in 482 Asian HCV-2 patients treated with the standard of care. Because the first three SNPs were in very strong linkage disequilibrium with one another (r2 = 0.94-0.96), rs8099917 and rs10853728 were selected for an analysis of their influence on the achievement of rapid virological response [RVR; seronegativity for hepatitis C virus (HCV) RNA in treatment week 4] and sustained virological response (SVR; seronegativity for HCV RNA throughout 24 weeks of posttreatment follow-up). The rs10853728 genotype did not predict RVR or SVR in HCV-2 patients. However, patients with the rs8099917 TT genotype, in comparison with patients with GT/GG genotypes, had a significantly higher rate of achieving RVR (85.2% versus 72.0%, P = 0.017) but did have not a significantly higher rate of achieving SVR (89.4% versus 86.0%). Multivariate analysis revealed that a baseline HCV viral load

  • role of Interleukin 28B polymorphisms in the treatment of hepatitis c virus genotype 2 infection in asian patients
    Hepatology, 2011
    Co-Authors: Chung Feng Huang, Jee-fu Huang, Jeng Fu Yang, Zu Yau Lin, Shinn Cherng Chen, L.-y. Wang, Ning-chia Chang, Ming-yuh Hsieh, Wen-yu Chang, Chiayen Dai
    Abstract:

    Genome-wide association studies have linked single nucleotide polymorphisms (SNPs) near the Interleukin-28B gene to the hepatitis C virus genotype 1 (HCV-1) response to peginterferon/ribavirin treatment. We aimed to explore the impact on the treatment outcomes of Asian HCV-2 patients. We determined rs8105790, rs8099917, rs4803219, and rs10853728 to be candidate SNPs in 482 Asian HCV-2 patients treated with the standard of care. Because the first three SNPs were in very strong linkage disequilibrium with one another (r2 = 0.94-0.96), rs8099917 and rs10853728 were selected for an analysis of their influence on the achievement of rapid virological response [RVR; seronegativity for hepatitis C virus (HCV) RNA in treatment week 4] and sustained virological response (SVR; seronegativity for HCV RNA throughout 24 weeks of posttreatment follow-up). The rs10853728 genotype did not predict RVR or SVR in HCV-2 patients. However, patients with the rs8099917 TT genotype, in comparison with patients with GT/GG genotypes, had a significantly higher rate of achieving RVR (85.2% versus 72.0%, P = 0.017) but did have not a significantly higher rate of achieving SVR (89.4% versus 86.0%). Multivariate analysis revealed that a baseline HCV viral load <400,000 IU/mL was the strongest predictor of RVR [odds ratio (OR) = 4.27, 95% confidence interval (CI) = 2.31-7.87, P < 0.001], and this was followed by advanced liver fibrosis (OR = 0.28, 95% CI = 0.15-0.53, P < 0.001), the carriage of the rs8099917 TT genotype (OR = 3.10, 95% CI = 1.34-7.21, P = 0.008), and the pretreatment level of aspartate aminotransferase (OR = 0.996, 95% CI = 0.99-1.00, P = 0.04). Nevertheless, the achievement of RVR was the single predictor of SVR with an OR of 19.37 (95% CI = 8.89-42.23, P < 0.001), whereas the rs8099917 genotypes played no role in achieving SVR with or without RVR. Conclusion: The rs8099917 TT genotype is significantly independently predictive of RVR, which is the single best predictor of SVR, in Asian HCV-2 patients. (Hepatology 2011)

Jee-fu Huang - One of the best experts on this subject based on the ideXlab platform.

  • Interleukin 28B genetic variants in identification of hepatitis c virus genotype 1 patients responding to 24 weeks peginterferon ribavirin
    Journal of Hepatology, 2012
    Co-Authors: Chung Feng Huang, Jee-fu Huang, Jeng Fu Yang, Ming Yen Hsieh, Zu Yau Lin, Shinn Cherng Chen, L.-y. Wang, Suh Hang Hank Juo, Ku Chung Chen, Wan-long Chuang
    Abstract:

    Background & Aims A substantial proportion of hepatitis C virus genotype 1 (HCV-1) patients achieved a sustained virological response (SVR, HCV RNA seronegative throughout 24weeks of post-treatment follow-up) after 24weeks peginterferon/ribavirin therapy. We explored the role of Interleukin-28B genotype in identifying patients who responded to the regimen. Methods Interleukin-28B rs8099917 genotype was determined in 226 HCV-1 patients with 24weeks peginterferon/ribavirin. Results Compared to patients with rs8099917 TG/GG genotype, those with TT genotype had significantly higher rapid virological response (RVR, HCV RNA seronegative at treatment week 4, 54.0% vs. 17.9%, p vs . 25.6%, p vs . 54.5%, p =0.01). Logistic regression analysis revealed that the strongest factor predictive of a RVR was the carriage of rs8099917 TT genotype (odds ratio/ 95% confidence intervals [OR/CI]: 6.24/2.34–16.63), followed by lower viral loads (OR/CI: 5.29/2.81–9.93) and age (OR/CI:0.94/0.91–9.97). The most important factor predictive of an SVR was the attainment of a RVR (OR/CI: 22.23/9.22–53.58), followed by the carriage of rs8099917 TT genotype (OR/CI: 3.38/1.18–9.65), lower viral loads (OR/CI: 2.23/1.00–4.93) and ribavirin exposure dose (OR/CI: 1.17/1.06–1.30). The determinant power of rs8099917 genotype on SVR was mainly restricted to non-RVR patients, particularly those with higher baseline viral loads. Combination of the two pretreatment predictors, Interleukin-28B genotype and baseline viral loads, could predict treatment efficacy with a positive predictive value of 80% and a negative predictive value of 91%. Conclusions Interleukin-28B genotype could help identifying patients who are or are not candidates for an abbreviated regimen before treatment.

  • Host Interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1.
    Antiviral research, 2011
    Co-Authors: Chung Feng Huang, Jee-fu Huang, Jeng Fu Yang, Ming Yen Hsieh, Zu Yau Lin, Shinn Cherng Chen, L.-y. Wang, Ming-lun Yeh, Edward Hsi, Suh Hang Hank Juo
    Abstract:

    Abstract Background Both Interleukin-28B genetic variants and on-treatment virological responses are factors predictive of treatment outcome in hepatitis C virus genotype 1 (HCV-1) patients. We aimed to compare the clinical significance of the two factors. Methods Rs8099917 genotype and on-treatment responses were determined in 182 HCV-1 patients with 48-week peginterferon/ribavirin. Results Comparing to patients with rs8099917 TG/GG genotype, those with TT genotype had significantly higher rapid virological response (RVR, 46.2% vs. 19.2%, P  = 0.01) and sustained virological response (SVR, 85.3% vs. 42.3%, P Conclusions Rs8099917 TT genotype is significantly independently predictive of on-treatment virological responses, which were the major determinants of an SVR, in Asian HCV-1 patients.

  • Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.
    Journal of hepatology, 2011
    Co-Authors: Chung Feng Huang, Jee-fu Huang, Jeng Fu Yang, Ming Yen Hsieh, Zu Yau Lin, Shinn Cherng Chen, L.-y. Wang, Suh Hang Hank Juo, Ku Chung Chen, Wan-long Chuang
    Abstract:

    Background & Aims A substantial proportion of hepatitis C virus genotype 1 (HCV-1) patients achieved a sustained virological response (SVR, HCV RNA seronegative throughout 24weeks of post-treatment follow-up) after 24weeks peginterferon/ribavirin therapy. We explored the role of Interleukin-28B genotype in identifying patients who responded to the regimen. Methods Interleukin-28B rs8099917 genotype was determined in 226 HCV-1 patients with 24weeks peginterferon/ribavirin. Results Compared to patients with rs8099917 TG/GG genotype, those with TT genotype had significantly higher rapid virological response (RVR, HCV RNA seronegative at treatment week 4, 54.0% vs. 17.9%, p vs . 25.6%, p vs . 54.5%, p =0.01). Logistic regression analysis revealed that the strongest factor predictive of a RVR was the carriage of rs8099917 TT genotype (odds ratio/ 95% confidence intervals [OR/CI]: 6.24/2.34–16.63), followed by lower viral loads (OR/CI: 5.29/2.81–9.93) and age (OR/CI:0.94/0.91–9.97). The most important factor predictive of an SVR was the attainment of a RVR (OR/CI: 22.23/9.22–53.58), followed by the carriage of rs8099917 TT genotype (OR/CI: 3.38/1.18–9.65), lower viral loads (OR/CI: 2.23/1.00–4.93) and ribavirin exposure dose (OR/CI: 1.17/1.06–1.30). The determinant power of rs8099917 genotype on SVR was mainly restricted to non-RVR patients, particularly those with higher baseline viral loads. Combination of the two pretreatment predictors, Interleukin-28B genotype and baseline viral loads, could predict treatment efficacy with a positive predictive value of 80% and a negative predictive value of 91%. Conclusions Interleukin-28B genotype could help identifying patients who are or are not candidates for an abbreviated regimen before treatment.

  • Role of Interleukin‐28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients
    Hepatology (Baltimore Md.), 2011
    Co-Authors: Chung Feng Huang, Jee-fu Huang, Jeng Fu Yang, Zu Yau Lin, Shinn Cherng Chen, L.-y. Wang, Ning-chia Chang, Ming-yuh Hsieh, Wen-yu Chang
    Abstract:

    Genome-wide association studies have linked single nucleotide polymorphisms (SNPs) near the Interleukin-28B gene to the hepatitis C virus genotype 1 (HCV-1) response to peginterferon/ribavirin treatment. We aimed to explore the impact on the treatment outcomes of Asian HCV-2 patients. We determined rs8105790, rs8099917, rs4803219, and rs10853728 to be candidate SNPs in 482 Asian HCV-2 patients treated with the standard of care. Because the first three SNPs were in very strong linkage disequilibrium with one another (r2 = 0.94-0.96), rs8099917 and rs10853728 were selected for an analysis of their influence on the achievement of rapid virological response [RVR; seronegativity for hepatitis C virus (HCV) RNA in treatment week 4] and sustained virological response (SVR; seronegativity for HCV RNA throughout 24 weeks of posttreatment follow-up). The rs10853728 genotype did not predict RVR or SVR in HCV-2 patients. However, patients with the rs8099917 TT genotype, in comparison with patients with GT/GG genotypes, had a significantly higher rate of achieving RVR (85.2% versus 72.0%, P = 0.017) but did have not a significantly higher rate of achieving SVR (89.4% versus 86.0%). Multivariate analysis revealed that a baseline HCV viral load

  • role of Interleukin 28B polymorphisms in the treatment of hepatitis c virus genotype 2 infection in asian patients
    Hepatology, 2011
    Co-Authors: Chung Feng Huang, Jee-fu Huang, Jeng Fu Yang, Zu Yau Lin, Shinn Cherng Chen, L.-y. Wang, Ning-chia Chang, Ming-yuh Hsieh, Wen-yu Chang, Chiayen Dai
    Abstract:

    Genome-wide association studies have linked single nucleotide polymorphisms (SNPs) near the Interleukin-28B gene to the hepatitis C virus genotype 1 (HCV-1) response to peginterferon/ribavirin treatment. We aimed to explore the impact on the treatment outcomes of Asian HCV-2 patients. We determined rs8105790, rs8099917, rs4803219, and rs10853728 to be candidate SNPs in 482 Asian HCV-2 patients treated with the standard of care. Because the first three SNPs were in very strong linkage disequilibrium with one another (r2 = 0.94-0.96), rs8099917 and rs10853728 were selected for an analysis of their influence on the achievement of rapid virological response [RVR; seronegativity for hepatitis C virus (HCV) RNA in treatment week 4] and sustained virological response (SVR; seronegativity for HCV RNA throughout 24 weeks of posttreatment follow-up). The rs10853728 genotype did not predict RVR or SVR in HCV-2 patients. However, patients with the rs8099917 TT genotype, in comparison with patients with GT/GG genotypes, had a significantly higher rate of achieving RVR (85.2% versus 72.0%, P = 0.017) but did have not a significantly higher rate of achieving SVR (89.4% versus 86.0%). Multivariate analysis revealed that a baseline HCV viral load <400,000 IU/mL was the strongest predictor of RVR [odds ratio (OR) = 4.27, 95% confidence interval (CI) = 2.31-7.87, P < 0.001], and this was followed by advanced liver fibrosis (OR = 0.28, 95% CI = 0.15-0.53, P < 0.001), the carriage of the rs8099917 TT genotype (OR = 3.10, 95% CI = 1.34-7.21, P = 0.008), and the pretreatment level of aspartate aminotransferase (OR = 0.996, 95% CI = 0.99-1.00, P = 0.04). Nevertheless, the achievement of RVR was the single predictor of SVR with an OR of 19.37 (95% CI = 8.89-42.23, P < 0.001), whereas the rs8099917 genotypes played no role in achieving SVR with or without RVR. Conclusion: The rs8099917 TT genotype is significantly independently predictive of RVR, which is the single best predictor of SVR, in Asian HCV-2 patients. (Hepatology 2011)

Jeng Fu Yang - One of the best experts on this subject based on the ideXlab platform.

  • Interleukin 28B genetic variants in identification of hepatitis c virus genotype 1 patients responding to 24 weeks peginterferon ribavirin
    Journal of Hepatology, 2012
    Co-Authors: Chung Feng Huang, Jee-fu Huang, Jeng Fu Yang, Ming Yen Hsieh, Zu Yau Lin, Shinn Cherng Chen, L.-y. Wang, Suh Hang Hank Juo, Ku Chung Chen, Wan-long Chuang
    Abstract:

    Background & Aims A substantial proportion of hepatitis C virus genotype 1 (HCV-1) patients achieved a sustained virological response (SVR, HCV RNA seronegative throughout 24weeks of post-treatment follow-up) after 24weeks peginterferon/ribavirin therapy. We explored the role of Interleukin-28B genotype in identifying patients who responded to the regimen. Methods Interleukin-28B rs8099917 genotype was determined in 226 HCV-1 patients with 24weeks peginterferon/ribavirin. Results Compared to patients with rs8099917 TG/GG genotype, those with TT genotype had significantly higher rapid virological response (RVR, HCV RNA seronegative at treatment week 4, 54.0% vs. 17.9%, p vs . 25.6%, p vs . 54.5%, p =0.01). Logistic regression analysis revealed that the strongest factor predictive of a RVR was the carriage of rs8099917 TT genotype (odds ratio/ 95% confidence intervals [OR/CI]: 6.24/2.34–16.63), followed by lower viral loads (OR/CI: 5.29/2.81–9.93) and age (OR/CI:0.94/0.91–9.97). The most important factor predictive of an SVR was the attainment of a RVR (OR/CI: 22.23/9.22–53.58), followed by the carriage of rs8099917 TT genotype (OR/CI: 3.38/1.18–9.65), lower viral loads (OR/CI: 2.23/1.00–4.93) and ribavirin exposure dose (OR/CI: 1.17/1.06–1.30). The determinant power of rs8099917 genotype on SVR was mainly restricted to non-RVR patients, particularly those with higher baseline viral loads. Combination of the two pretreatment predictors, Interleukin-28B genotype and baseline viral loads, could predict treatment efficacy with a positive predictive value of 80% and a negative predictive value of 91%. Conclusions Interleukin-28B genotype could help identifying patients who are or are not candidates for an abbreviated regimen before treatment.

  • Host Interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1.
    Antiviral research, 2011
    Co-Authors: Chung Feng Huang, Jee-fu Huang, Jeng Fu Yang, Ming Yen Hsieh, Zu Yau Lin, Shinn Cherng Chen, L.-y. Wang, Ming-lun Yeh, Edward Hsi, Suh Hang Hank Juo
    Abstract:

    Abstract Background Both Interleukin-28B genetic variants and on-treatment virological responses are factors predictive of treatment outcome in hepatitis C virus genotype 1 (HCV-1) patients. We aimed to compare the clinical significance of the two factors. Methods Rs8099917 genotype and on-treatment responses were determined in 182 HCV-1 patients with 48-week peginterferon/ribavirin. Results Comparing to patients with rs8099917 TG/GG genotype, those with TT genotype had significantly higher rapid virological response (RVR, 46.2% vs. 19.2%, P  = 0.01) and sustained virological response (SVR, 85.3% vs. 42.3%, P Conclusions Rs8099917 TT genotype is significantly independently predictive of on-treatment virological responses, which were the major determinants of an SVR, in Asian HCV-1 patients.

  • Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.
    Journal of hepatology, 2011
    Co-Authors: Chung Feng Huang, Jee-fu Huang, Jeng Fu Yang, Ming Yen Hsieh, Zu Yau Lin, Shinn Cherng Chen, L.-y. Wang, Suh Hang Hank Juo, Ku Chung Chen, Wan-long Chuang
    Abstract:

    Background & Aims A substantial proportion of hepatitis C virus genotype 1 (HCV-1) patients achieved a sustained virological response (SVR, HCV RNA seronegative throughout 24weeks of post-treatment follow-up) after 24weeks peginterferon/ribavirin therapy. We explored the role of Interleukin-28B genotype in identifying patients who responded to the regimen. Methods Interleukin-28B rs8099917 genotype was determined in 226 HCV-1 patients with 24weeks peginterferon/ribavirin. Results Compared to patients with rs8099917 TG/GG genotype, those with TT genotype had significantly higher rapid virological response (RVR, HCV RNA seronegative at treatment week 4, 54.0% vs. 17.9%, p vs . 25.6%, p vs . 54.5%, p =0.01). Logistic regression analysis revealed that the strongest factor predictive of a RVR was the carriage of rs8099917 TT genotype (odds ratio/ 95% confidence intervals [OR/CI]: 6.24/2.34–16.63), followed by lower viral loads (OR/CI: 5.29/2.81–9.93) and age (OR/CI:0.94/0.91–9.97). The most important factor predictive of an SVR was the attainment of a RVR (OR/CI: 22.23/9.22–53.58), followed by the carriage of rs8099917 TT genotype (OR/CI: 3.38/1.18–9.65), lower viral loads (OR/CI: 2.23/1.00–4.93) and ribavirin exposure dose (OR/CI: 1.17/1.06–1.30). The determinant power of rs8099917 genotype on SVR was mainly restricted to non-RVR patients, particularly those with higher baseline viral loads. Combination of the two pretreatment predictors, Interleukin-28B genotype and baseline viral loads, could predict treatment efficacy with a positive predictive value of 80% and a negative predictive value of 91%. Conclusions Interleukin-28B genotype could help identifying patients who are or are not candidates for an abbreviated regimen before treatment.

  • Role of Interleukin‐28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients
    Hepatology (Baltimore Md.), 2011
    Co-Authors: Chung Feng Huang, Jee-fu Huang, Jeng Fu Yang, Zu Yau Lin, Shinn Cherng Chen, L.-y. Wang, Ning-chia Chang, Ming-yuh Hsieh, Wen-yu Chang
    Abstract:

    Genome-wide association studies have linked single nucleotide polymorphisms (SNPs) near the Interleukin-28B gene to the hepatitis C virus genotype 1 (HCV-1) response to peginterferon/ribavirin treatment. We aimed to explore the impact on the treatment outcomes of Asian HCV-2 patients. We determined rs8105790, rs8099917, rs4803219, and rs10853728 to be candidate SNPs in 482 Asian HCV-2 patients treated with the standard of care. Because the first three SNPs were in very strong linkage disequilibrium with one another (r2 = 0.94-0.96), rs8099917 and rs10853728 were selected for an analysis of their influence on the achievement of rapid virological response [RVR; seronegativity for hepatitis C virus (HCV) RNA in treatment week 4] and sustained virological response (SVR; seronegativity for HCV RNA throughout 24 weeks of posttreatment follow-up). The rs10853728 genotype did not predict RVR or SVR in HCV-2 patients. However, patients with the rs8099917 TT genotype, in comparison with patients with GT/GG genotypes, had a significantly higher rate of achieving RVR (85.2% versus 72.0%, P = 0.017) but did have not a significantly higher rate of achieving SVR (89.4% versus 86.0%). Multivariate analysis revealed that a baseline HCV viral load

  • role of Interleukin 28B polymorphisms in the treatment of hepatitis c virus genotype 2 infection in asian patients
    Hepatology, 2011
    Co-Authors: Chung Feng Huang, Jee-fu Huang, Jeng Fu Yang, Zu Yau Lin, Shinn Cherng Chen, L.-y. Wang, Ning-chia Chang, Ming-yuh Hsieh, Wen-yu Chang, Chiayen Dai
    Abstract:

    Genome-wide association studies have linked single nucleotide polymorphisms (SNPs) near the Interleukin-28B gene to the hepatitis C virus genotype 1 (HCV-1) response to peginterferon/ribavirin treatment. We aimed to explore the impact on the treatment outcomes of Asian HCV-2 patients. We determined rs8105790, rs8099917, rs4803219, and rs10853728 to be candidate SNPs in 482 Asian HCV-2 patients treated with the standard of care. Because the first three SNPs were in very strong linkage disequilibrium with one another (r2 = 0.94-0.96), rs8099917 and rs10853728 were selected for an analysis of their influence on the achievement of rapid virological response [RVR; seronegativity for hepatitis C virus (HCV) RNA in treatment week 4] and sustained virological response (SVR; seronegativity for HCV RNA throughout 24 weeks of posttreatment follow-up). The rs10853728 genotype did not predict RVR or SVR in HCV-2 patients. However, patients with the rs8099917 TT genotype, in comparison with patients with GT/GG genotypes, had a significantly higher rate of achieving RVR (85.2% versus 72.0%, P = 0.017) but did have not a significantly higher rate of achieving SVR (89.4% versus 86.0%). Multivariate analysis revealed that a baseline HCV viral load <400,000 IU/mL was the strongest predictor of RVR [odds ratio (OR) = 4.27, 95% confidence interval (CI) = 2.31-7.87, P < 0.001], and this was followed by advanced liver fibrosis (OR = 0.28, 95% CI = 0.15-0.53, P < 0.001), the carriage of the rs8099917 TT genotype (OR = 3.10, 95% CI = 1.34-7.21, P = 0.008), and the pretreatment level of aspartate aminotransferase (OR = 0.996, 95% CI = 0.99-1.00, P = 0.04). Nevertheless, the achievement of RVR was the single predictor of SVR with an OR of 19.37 (95% CI = 8.89-42.23, P < 0.001), whereas the rs8099917 genotypes played no role in achieving SVR with or without RVR. Conclusion: The rs8099917 TT genotype is significantly independently predictive of RVR, which is the single best predictor of SVR, in Asian HCV-2 patients. (Hepatology 2011)

Zu Yau Lin - One of the best experts on this subject based on the ideXlab platform.

  • Interleukin 28B genetic variants in identification of hepatitis c virus genotype 1 patients responding to 24 weeks peginterferon ribavirin
    Journal of Hepatology, 2012
    Co-Authors: Chung Feng Huang, Jee-fu Huang, Jeng Fu Yang, Ming Yen Hsieh, Zu Yau Lin, Shinn Cherng Chen, L.-y. Wang, Suh Hang Hank Juo, Ku Chung Chen, Wan-long Chuang
    Abstract:

    Background & Aims A substantial proportion of hepatitis C virus genotype 1 (HCV-1) patients achieved a sustained virological response (SVR, HCV RNA seronegative throughout 24weeks of post-treatment follow-up) after 24weeks peginterferon/ribavirin therapy. We explored the role of Interleukin-28B genotype in identifying patients who responded to the regimen. Methods Interleukin-28B rs8099917 genotype was determined in 226 HCV-1 patients with 24weeks peginterferon/ribavirin. Results Compared to patients with rs8099917 TG/GG genotype, those with TT genotype had significantly higher rapid virological response (RVR, HCV RNA seronegative at treatment week 4, 54.0% vs. 17.9%, p vs . 25.6%, p vs . 54.5%, p =0.01). Logistic regression analysis revealed that the strongest factor predictive of a RVR was the carriage of rs8099917 TT genotype (odds ratio/ 95% confidence intervals [OR/CI]: 6.24/2.34–16.63), followed by lower viral loads (OR/CI: 5.29/2.81–9.93) and age (OR/CI:0.94/0.91–9.97). The most important factor predictive of an SVR was the attainment of a RVR (OR/CI: 22.23/9.22–53.58), followed by the carriage of rs8099917 TT genotype (OR/CI: 3.38/1.18–9.65), lower viral loads (OR/CI: 2.23/1.00–4.93) and ribavirin exposure dose (OR/CI: 1.17/1.06–1.30). The determinant power of rs8099917 genotype on SVR was mainly restricted to non-RVR patients, particularly those with higher baseline viral loads. Combination of the two pretreatment predictors, Interleukin-28B genotype and baseline viral loads, could predict treatment efficacy with a positive predictive value of 80% and a negative predictive value of 91%. Conclusions Interleukin-28B genotype could help identifying patients who are or are not candidates for an abbreviated regimen before treatment.

  • Host Interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1.
    Antiviral research, 2011
    Co-Authors: Chung Feng Huang, Jee-fu Huang, Jeng Fu Yang, Ming Yen Hsieh, Zu Yau Lin, Shinn Cherng Chen, L.-y. Wang, Ming-lun Yeh, Edward Hsi, Suh Hang Hank Juo
    Abstract:

    Abstract Background Both Interleukin-28B genetic variants and on-treatment virological responses are factors predictive of treatment outcome in hepatitis C virus genotype 1 (HCV-1) patients. We aimed to compare the clinical significance of the two factors. Methods Rs8099917 genotype and on-treatment responses were determined in 182 HCV-1 patients with 48-week peginterferon/ribavirin. Results Comparing to patients with rs8099917 TG/GG genotype, those with TT genotype had significantly higher rapid virological response (RVR, 46.2% vs. 19.2%, P  = 0.01) and sustained virological response (SVR, 85.3% vs. 42.3%, P Conclusions Rs8099917 TT genotype is significantly independently predictive of on-treatment virological responses, which were the major determinants of an SVR, in Asian HCV-1 patients.

  • Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.
    Journal of hepatology, 2011
    Co-Authors: Chung Feng Huang, Jee-fu Huang, Jeng Fu Yang, Ming Yen Hsieh, Zu Yau Lin, Shinn Cherng Chen, L.-y. Wang, Suh Hang Hank Juo, Ku Chung Chen, Wan-long Chuang
    Abstract:

    Background & Aims A substantial proportion of hepatitis C virus genotype 1 (HCV-1) patients achieved a sustained virological response (SVR, HCV RNA seronegative throughout 24weeks of post-treatment follow-up) after 24weeks peginterferon/ribavirin therapy. We explored the role of Interleukin-28B genotype in identifying patients who responded to the regimen. Methods Interleukin-28B rs8099917 genotype was determined in 226 HCV-1 patients with 24weeks peginterferon/ribavirin. Results Compared to patients with rs8099917 TG/GG genotype, those with TT genotype had significantly higher rapid virological response (RVR, HCV RNA seronegative at treatment week 4, 54.0% vs. 17.9%, p vs . 25.6%, p vs . 54.5%, p =0.01). Logistic regression analysis revealed that the strongest factor predictive of a RVR was the carriage of rs8099917 TT genotype (odds ratio/ 95% confidence intervals [OR/CI]: 6.24/2.34–16.63), followed by lower viral loads (OR/CI: 5.29/2.81–9.93) and age (OR/CI:0.94/0.91–9.97). The most important factor predictive of an SVR was the attainment of a RVR (OR/CI: 22.23/9.22–53.58), followed by the carriage of rs8099917 TT genotype (OR/CI: 3.38/1.18–9.65), lower viral loads (OR/CI: 2.23/1.00–4.93) and ribavirin exposure dose (OR/CI: 1.17/1.06–1.30). The determinant power of rs8099917 genotype on SVR was mainly restricted to non-RVR patients, particularly those with higher baseline viral loads. Combination of the two pretreatment predictors, Interleukin-28B genotype and baseline viral loads, could predict treatment efficacy with a positive predictive value of 80% and a negative predictive value of 91%. Conclusions Interleukin-28B genotype could help identifying patients who are or are not candidates for an abbreviated regimen before treatment.

  • Role of Interleukin‐28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients
    Hepatology (Baltimore Md.), 2011
    Co-Authors: Chung Feng Huang, Jee-fu Huang, Jeng Fu Yang, Zu Yau Lin, Shinn Cherng Chen, L.-y. Wang, Ning-chia Chang, Ming-yuh Hsieh, Wen-yu Chang
    Abstract:

    Genome-wide association studies have linked single nucleotide polymorphisms (SNPs) near the Interleukin-28B gene to the hepatitis C virus genotype 1 (HCV-1) response to peginterferon/ribavirin treatment. We aimed to explore the impact on the treatment outcomes of Asian HCV-2 patients. We determined rs8105790, rs8099917, rs4803219, and rs10853728 to be candidate SNPs in 482 Asian HCV-2 patients treated with the standard of care. Because the first three SNPs were in very strong linkage disequilibrium with one another (r2 = 0.94-0.96), rs8099917 and rs10853728 were selected for an analysis of their influence on the achievement of rapid virological response [RVR; seronegativity for hepatitis C virus (HCV) RNA in treatment week 4] and sustained virological response (SVR; seronegativity for HCV RNA throughout 24 weeks of posttreatment follow-up). The rs10853728 genotype did not predict RVR or SVR in HCV-2 patients. However, patients with the rs8099917 TT genotype, in comparison with patients with GT/GG genotypes, had a significantly higher rate of achieving RVR (85.2% versus 72.0%, P = 0.017) but did have not a significantly higher rate of achieving SVR (89.4% versus 86.0%). Multivariate analysis revealed that a baseline HCV viral load

  • role of Interleukin 28B polymorphisms in the treatment of hepatitis c virus genotype 2 infection in asian patients
    Hepatology, 2011
    Co-Authors: Chung Feng Huang, Jee-fu Huang, Jeng Fu Yang, Zu Yau Lin, Shinn Cherng Chen, L.-y. Wang, Ning-chia Chang, Ming-yuh Hsieh, Wen-yu Chang, Chiayen Dai
    Abstract:

    Genome-wide association studies have linked single nucleotide polymorphisms (SNPs) near the Interleukin-28B gene to the hepatitis C virus genotype 1 (HCV-1) response to peginterferon/ribavirin treatment. We aimed to explore the impact on the treatment outcomes of Asian HCV-2 patients. We determined rs8105790, rs8099917, rs4803219, and rs10853728 to be candidate SNPs in 482 Asian HCV-2 patients treated with the standard of care. Because the first three SNPs were in very strong linkage disequilibrium with one another (r2 = 0.94-0.96), rs8099917 and rs10853728 were selected for an analysis of their influence on the achievement of rapid virological response [RVR; seronegativity for hepatitis C virus (HCV) RNA in treatment week 4] and sustained virological response (SVR; seronegativity for HCV RNA throughout 24 weeks of posttreatment follow-up). The rs10853728 genotype did not predict RVR or SVR in HCV-2 patients. However, patients with the rs8099917 TT genotype, in comparison with patients with GT/GG genotypes, had a significantly higher rate of achieving RVR (85.2% versus 72.0%, P = 0.017) but did have not a significantly higher rate of achieving SVR (89.4% versus 86.0%). Multivariate analysis revealed that a baseline HCV viral load <400,000 IU/mL was the strongest predictor of RVR [odds ratio (OR) = 4.27, 95% confidence interval (CI) = 2.31-7.87, P < 0.001], and this was followed by advanced liver fibrosis (OR = 0.28, 95% CI = 0.15-0.53, P < 0.001), the carriage of the rs8099917 TT genotype (OR = 3.10, 95% CI = 1.34-7.21, P = 0.008), and the pretreatment level of aspartate aminotransferase (OR = 0.996, 95% CI = 0.99-1.00, P = 0.04). Nevertheless, the achievement of RVR was the single predictor of SVR with an OR of 19.37 (95% CI = 8.89-42.23, P < 0.001), whereas the rs8099917 genotypes played no role in achieving SVR with or without RVR. Conclusion: The rs8099917 TT genotype is significantly independently predictive of RVR, which is the single best predictor of SVR, in Asian HCV-2 patients. (Hepatology 2011)

Shinn Cherng Chen - One of the best experts on this subject based on the ideXlab platform.

  • Interleukin 28B genetic variants in identification of hepatitis c virus genotype 1 patients responding to 24 weeks peginterferon ribavirin
    Journal of Hepatology, 2012
    Co-Authors: Chung Feng Huang, Jee-fu Huang, Jeng Fu Yang, Ming Yen Hsieh, Zu Yau Lin, Shinn Cherng Chen, L.-y. Wang, Suh Hang Hank Juo, Ku Chung Chen, Wan-long Chuang
    Abstract:

    Background & Aims A substantial proportion of hepatitis C virus genotype 1 (HCV-1) patients achieved a sustained virological response (SVR, HCV RNA seronegative throughout 24weeks of post-treatment follow-up) after 24weeks peginterferon/ribavirin therapy. We explored the role of Interleukin-28B genotype in identifying patients who responded to the regimen. Methods Interleukin-28B rs8099917 genotype was determined in 226 HCV-1 patients with 24weeks peginterferon/ribavirin. Results Compared to patients with rs8099917 TG/GG genotype, those with TT genotype had significantly higher rapid virological response (RVR, HCV RNA seronegative at treatment week 4, 54.0% vs. 17.9%, p vs . 25.6%, p vs . 54.5%, p =0.01). Logistic regression analysis revealed that the strongest factor predictive of a RVR was the carriage of rs8099917 TT genotype (odds ratio/ 95% confidence intervals [OR/CI]: 6.24/2.34–16.63), followed by lower viral loads (OR/CI: 5.29/2.81–9.93) and age (OR/CI:0.94/0.91–9.97). The most important factor predictive of an SVR was the attainment of a RVR (OR/CI: 22.23/9.22–53.58), followed by the carriage of rs8099917 TT genotype (OR/CI: 3.38/1.18–9.65), lower viral loads (OR/CI: 2.23/1.00–4.93) and ribavirin exposure dose (OR/CI: 1.17/1.06–1.30). The determinant power of rs8099917 genotype on SVR was mainly restricted to non-RVR patients, particularly those with higher baseline viral loads. Combination of the two pretreatment predictors, Interleukin-28B genotype and baseline viral loads, could predict treatment efficacy with a positive predictive value of 80% and a negative predictive value of 91%. Conclusions Interleukin-28B genotype could help identifying patients who are or are not candidates for an abbreviated regimen before treatment.

  • Host Interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1.
    Antiviral research, 2011
    Co-Authors: Chung Feng Huang, Jee-fu Huang, Jeng Fu Yang, Ming Yen Hsieh, Zu Yau Lin, Shinn Cherng Chen, L.-y. Wang, Ming-lun Yeh, Edward Hsi, Suh Hang Hank Juo
    Abstract:

    Abstract Background Both Interleukin-28B genetic variants and on-treatment virological responses are factors predictive of treatment outcome in hepatitis C virus genotype 1 (HCV-1) patients. We aimed to compare the clinical significance of the two factors. Methods Rs8099917 genotype and on-treatment responses were determined in 182 HCV-1 patients with 48-week peginterferon/ribavirin. Results Comparing to patients with rs8099917 TG/GG genotype, those with TT genotype had significantly higher rapid virological response (RVR, 46.2% vs. 19.2%, P  = 0.01) and sustained virological response (SVR, 85.3% vs. 42.3%, P Conclusions Rs8099917 TT genotype is significantly independently predictive of on-treatment virological responses, which were the major determinants of an SVR, in Asian HCV-1 patients.

  • Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.
    Journal of hepatology, 2011
    Co-Authors: Chung Feng Huang, Jee-fu Huang, Jeng Fu Yang, Ming Yen Hsieh, Zu Yau Lin, Shinn Cherng Chen, L.-y. Wang, Suh Hang Hank Juo, Ku Chung Chen, Wan-long Chuang
    Abstract:

    Background & Aims A substantial proportion of hepatitis C virus genotype 1 (HCV-1) patients achieved a sustained virological response (SVR, HCV RNA seronegative throughout 24weeks of post-treatment follow-up) after 24weeks peginterferon/ribavirin therapy. We explored the role of Interleukin-28B genotype in identifying patients who responded to the regimen. Methods Interleukin-28B rs8099917 genotype was determined in 226 HCV-1 patients with 24weeks peginterferon/ribavirin. Results Compared to patients with rs8099917 TG/GG genotype, those with TT genotype had significantly higher rapid virological response (RVR, HCV RNA seronegative at treatment week 4, 54.0% vs. 17.9%, p vs . 25.6%, p vs . 54.5%, p =0.01). Logistic regression analysis revealed that the strongest factor predictive of a RVR was the carriage of rs8099917 TT genotype (odds ratio/ 95% confidence intervals [OR/CI]: 6.24/2.34–16.63), followed by lower viral loads (OR/CI: 5.29/2.81–9.93) and age (OR/CI:0.94/0.91–9.97). The most important factor predictive of an SVR was the attainment of a RVR (OR/CI: 22.23/9.22–53.58), followed by the carriage of rs8099917 TT genotype (OR/CI: 3.38/1.18–9.65), lower viral loads (OR/CI: 2.23/1.00–4.93) and ribavirin exposure dose (OR/CI: 1.17/1.06–1.30). The determinant power of rs8099917 genotype on SVR was mainly restricted to non-RVR patients, particularly those with higher baseline viral loads. Combination of the two pretreatment predictors, Interleukin-28B genotype and baseline viral loads, could predict treatment efficacy with a positive predictive value of 80% and a negative predictive value of 91%. Conclusions Interleukin-28B genotype could help identifying patients who are or are not candidates for an abbreviated regimen before treatment.

  • Role of Interleukin‐28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients
    Hepatology (Baltimore Md.), 2011
    Co-Authors: Chung Feng Huang, Jee-fu Huang, Jeng Fu Yang, Zu Yau Lin, Shinn Cherng Chen, L.-y. Wang, Ning-chia Chang, Ming-yuh Hsieh, Wen-yu Chang
    Abstract:

    Genome-wide association studies have linked single nucleotide polymorphisms (SNPs) near the Interleukin-28B gene to the hepatitis C virus genotype 1 (HCV-1) response to peginterferon/ribavirin treatment. We aimed to explore the impact on the treatment outcomes of Asian HCV-2 patients. We determined rs8105790, rs8099917, rs4803219, and rs10853728 to be candidate SNPs in 482 Asian HCV-2 patients treated with the standard of care. Because the first three SNPs were in very strong linkage disequilibrium with one another (r2 = 0.94-0.96), rs8099917 and rs10853728 were selected for an analysis of their influence on the achievement of rapid virological response [RVR; seronegativity for hepatitis C virus (HCV) RNA in treatment week 4] and sustained virological response (SVR; seronegativity for HCV RNA throughout 24 weeks of posttreatment follow-up). The rs10853728 genotype did not predict RVR or SVR in HCV-2 patients. However, patients with the rs8099917 TT genotype, in comparison with patients with GT/GG genotypes, had a significantly higher rate of achieving RVR (85.2% versus 72.0%, P = 0.017) but did have not a significantly higher rate of achieving SVR (89.4% versus 86.0%). Multivariate analysis revealed that a baseline HCV viral load

  • role of Interleukin 28B polymorphisms in the treatment of hepatitis c virus genotype 2 infection in asian patients
    Hepatology, 2011
    Co-Authors: Chung Feng Huang, Jee-fu Huang, Jeng Fu Yang, Zu Yau Lin, Shinn Cherng Chen, L.-y. Wang, Ning-chia Chang, Ming-yuh Hsieh, Wen-yu Chang, Chiayen Dai
    Abstract:

    Genome-wide association studies have linked single nucleotide polymorphisms (SNPs) near the Interleukin-28B gene to the hepatitis C virus genotype 1 (HCV-1) response to peginterferon/ribavirin treatment. We aimed to explore the impact on the treatment outcomes of Asian HCV-2 patients. We determined rs8105790, rs8099917, rs4803219, and rs10853728 to be candidate SNPs in 482 Asian HCV-2 patients treated with the standard of care. Because the first three SNPs were in very strong linkage disequilibrium with one another (r2 = 0.94-0.96), rs8099917 and rs10853728 were selected for an analysis of their influence on the achievement of rapid virological response [RVR; seronegativity for hepatitis C virus (HCV) RNA in treatment week 4] and sustained virological response (SVR; seronegativity for HCV RNA throughout 24 weeks of posttreatment follow-up). The rs10853728 genotype did not predict RVR or SVR in HCV-2 patients. However, patients with the rs8099917 TT genotype, in comparison with patients with GT/GG genotypes, had a significantly higher rate of achieving RVR (85.2% versus 72.0%, P = 0.017) but did have not a significantly higher rate of achieving SVR (89.4% versus 86.0%). Multivariate analysis revealed that a baseline HCV viral load <400,000 IU/mL was the strongest predictor of RVR [odds ratio (OR) = 4.27, 95% confidence interval (CI) = 2.31-7.87, P < 0.001], and this was followed by advanced liver fibrosis (OR = 0.28, 95% CI = 0.15-0.53, P < 0.001), the carriage of the rs8099917 TT genotype (OR = 3.10, 95% CI = 1.34-7.21, P = 0.008), and the pretreatment level of aspartate aminotransferase (OR = 0.996, 95% CI = 0.99-1.00, P = 0.04). Nevertheless, the achievement of RVR was the single predictor of SVR with an OR of 19.37 (95% CI = 8.89-42.23, P < 0.001), whereas the rs8099917 genotypes played no role in achieving SVR with or without RVR. Conclusion: The rs8099917 TT genotype is significantly independently predictive of RVR, which is the single best predictor of SVR, in Asian HCV-2 patients. (Hepatology 2011)